Skip to main content
SpringerLink
Log in

Liver Diseases

  • Chapter
  • First Online:
Clinical Molecular Diagnostics

Abstract

The liver, with four lobes of unequal size and shape, is a reddish-brown, wedge-shaped organ with dual blood supply. As the heaviest parenchymatous organ in the human body, it mainly lies in the right upper abdomen and a small part in the left rib region, that is, it is below the diaphragm, nearby the stomach, and covers the gallbladder (Fig. 33.1). Lobules, the functional units of the liver, are composed of millions of hepatocytes which are radially arranged in the center of central veins.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.

    Article  CAS  PubMed  Google Scholar 

  2. Yeo Y, Ho H, Yang H, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology. 2019;156:635–646.e639.

    Article  CAS  PubMed  Google Scholar 

  3. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388:1081–8.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Brook G, Bhagani S, Kulasegaram R, et al. United Kingdom national guideline on the management of the viral hepatitides A, B and C 2015. Int J STD AIDS. 2016;27:501–25.

    Article  PubMed  Google Scholar 

  5. Giersch K, Allweiss L, Volz T, et al. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol. 2017;66:460–2.

    Article  CAS  PubMed  Google Scholar 

  6. Shang HY, Cheng ZJ, Qi-Shui OU. Establishment of melt curve analysis for genotyping of hepatitis B virus. Chin J Clin Lab Sci. 2011;27:130−36.

    Google Scholar 

  7. Wang W, Liang H, Zeng Y, et al. Establishment of a novel two-probe real-time PCR for simultaneously quantification of hepatitis B virus DNA and distinguishing genotype B from non-B genotypes. Clin Chim Acta. 2014;437:168–74.

    Article  CAS  PubMed  Google Scholar 

  8. Zeng Y, Li D, Wang W, et al. Establishment of real time allele specific locked nucleic acid quantitative PCR for detection of HBV YIDD (ATT) mutation and evaluation of its application. PLoS One. 2014;9:e90029.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Liu C, Lin J, Chen H, et al. Detection of hepatitis B virus genotypic resistance mutations by coamplification at lower denaturation temperature-PCR coupled with Sanger sequencing. J Clin Microbiol. 2014;52:2933–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.

    Article  Google Scholar 

  11. Sghaier I, Brochot E, Loueslati BY, et al. Hepatitis C virus protein interaction network for HCV clearance and association of DAA to HCC occurrence via data mining approach: a systematic review and critical analysis. Rev Med Virol. 2019;29:e2033.

    Article  PubMed  Google Scholar 

  12. Qin Q, Smith MK, Wang L, et al. Hepatitis C virus infection in China: an emerging public health issue. J Viral Hepat. 2015;22:238–44.

    Article  PubMed  Google Scholar 

  13. Reddy R, Bruno S, Rossaro L, et al. Predictors of sustained virologic response among treatment-naïve patients with hepatitis C virus genotype 1 when treated with boceprevir (BOC) plus peginterferon alfa-2b-ribavirin (PR). Gastroenterology. 2011;140:S-943-S-943.

    Article  Google Scholar 

  14. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61:S58–68.

    Article  PubMed  Google Scholar 

  15. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521, 521.e511–516.

    Article  PubMed  Google Scholar 

  16. Davis GL, Alter MJ, El-Serag H, et al. Comprehensive analysis of mutations in the hepatitis delta virus genome based on full-length sequencing in a nationwide cohort study and evolutionary pattern during disease progression. Clin Microbiol Infect. 2015;21:510.e511–523.

    Google Scholar 

  17. Haffar S, Bazerbachi F, Lake JR. Making the case for the development of a vaccination against hepatitis E virus. Liver Int. 2015;35:311–6.

    Article  PubMed  Google Scholar 

  18. Cainelli F, Hortelano G, Negmetzhanov B, et al. Detection of hepatitis E antibodies in Kazakhstan: a pilot study. Cent Asian J Glob Health. 2018;7:324.

    PubMed  PubMed Central  Google Scholar 

  19. Kar P, Sengupta A. A guide to the management of hepatitis E infection during pregnancy. Expert Rev Gastroenterol Hepatol. 2019;13:205–11.

    Article  CAS  PubMed  Google Scholar 

  20. European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63:971–1004.

    Article  Google Scholar 

  21. Tanaka A, Mori M, Matsumoto K, et al. An increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res. 2019;49(8):881–9.

    Article  CAS  PubMed  Google Scholar 

  22. Yang F, Wang Q, Bian Z, et al. Autoimmune hepatitis: east meets west. J Gastroenterol Hepatol. 2015;30:1230–6.

    Article  PubMed  Google Scholar 

  23. Manns M, Gerken G, Kyriatsoulis A, et al. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet. 1987;1:292–4.

    Article  CAS  PubMed  Google Scholar 

  24. Golovanova EV, Lazebnik LB, Konev YV et al. [Autoimmune liver diseases: clinical features, diagnosis, treatment. Guidelines were approved by the XV Gastroenterological Scientific Society of Russia in 2015]. Eksp Klin Gastroenterol. 2015;7: 97–107.

    Google Scholar 

  25. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354:54–66.

    Article  CAS  PubMed  Google Scholar 

  26. Torgutalp M, Efe C, Babaoglu H, et al. Relationship between serum adenosine deaminase levels and liver histology in autoimmune hepatitis. World J Gastroenterol. 2017;23:3876–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Heneghan MA, Yeoman AD, Verma S, et al. Autoimmune hepatitis. Lancet. 2013;382:1433–44.

    Article  CAS  PubMed  Google Scholar 

  28. Czaja AJ. Autoimmune hepatitis in diverse ethnic populations and geographical regions. Expert Rev Gastroenterol Hepatol. 2013;7:365–85.

    Article  CAS  PubMed  Google Scholar 

  29. Hines IN, Kremer M, Isayama F, et al. Impaired liver regeneration and increased oval cell numbers following T cell-mediated hepatitis. Hepatology. 2007;46:229–41.

    Article  CAS  PubMed  Google Scholar 

  30. Liberal R, Longhi MS, Mieli-Vergani G, et al. Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol. 2011;25:653–64.

    Article  CAS  PubMed  Google Scholar 

  31. Donaldson PT. Genetics in autoimmune hepatitis. Semin Liver Dis. 2002;22:353–64.

    Article  CAS  PubMed  Google Scholar 

  32. Doherty DG, Donaldson PT, Underhill JA, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology. 1994;19:609–15.

    Article  CAS  PubMed  Google Scholar 

  33. Yoshizawa K, Matsumoto A, Ichijo T, et al. Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology. 2012;56:668–76.

    Article  PubMed  Google Scholar 

  34. Amarapurkar DN, Patel ND, Amarapurkar AD, et al. HLA genotyping in type-I autoimmune hepatitis in Western India. J Assoc Physicians India. 2003;51:967–9.

    CAS  PubMed  Google Scholar 

  35. Hassan N, Siddiqui AR, Abbas Z, et al. Clinical profile and HLA typing of autoimmune hepatitis from Pakistan. Hepat Mon. 2013;13:e13598.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Floreani A, Restrepo-Jimenez P, Secchi MF, et al. Etiopathogenesis of autoimmune hepatitis. J Autoimmun. 2018;95:133–43.

    Google Scholar 

  37. Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42:53–62.

    Article  PubMed  Google Scholar 

  38. Yeoman AD, Westbrook RH, Zen Y, et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol. 2014;61:876–82.

    Article  CAS  PubMed  Google Scholar 

  39. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112:18–35.

    Article  CAS  PubMed  Google Scholar 

  40. Chan EK, Damoiseaux J, Carballo OG, et al. Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015. Front Immunol. 2015;6:412.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Johnson GD, Holborow EJ, Glynn LE. Antibody to smooth muscle in patients with liver disease. Lancet. 1965;2:878–9.

    Article  CAS  PubMed  Google Scholar 

  42. Whittingham S, Irwin J, Mackay IR, et al. Smooth muscle autoantibody in “autoimmune” hepatitis. Gastroenterology. 1966;51:499–505.

    Article  CAS  PubMed  Google Scholar 

  43. Couto CA, Bittencourt PL, Porta G, et al. Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis. Hepatology. 2014;59:592–600.

    Article  CAS  PubMed  Google Scholar 

  44. Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol. 1973;15:331–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Lenzi M, Ballardini G, Fusconi M, et al. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet. 1990;335:258–9.

    Article  CAS  PubMed  Google Scholar 

  46. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet. 2000;355:1510–5.

    Article  CAS  PubMed  Google Scholar 

  47. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology. 2002;35:658–64.

    Article  CAS  PubMed  Google Scholar 

  48. Chen ZX, Shao JG, Shen Y, et al. Prognostic implications of antibodies to soluble liver antigen in autoimmune hepatitis: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2015;94:e953.

    Article  CAS  Google Scholar 

  49. Montano-Loza AJ, Shums Z, Norman GL, et al. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int. 2012;32:85–92.

    Article  CAS  PubMed  Google Scholar 

  50. Okazaki K, Uchida K, Koyabu M, et al. IgG4 cholangiopathy: current concept, diagnosis, and pathogenesis. J Hepatol. 2014;61:690–5.

    Article  CAS  PubMed  Google Scholar 

  51. Umemura T, Zen Y, Hamano H, et al. Clinical significance of immunoglobulin G4-associated autoimmune hepatitis. J Gastroenterol. 2011;46(Suppl 1):48–55.

    Article  CAS  PubMed  Google Scholar 

  52. Trivedi PJ, Hubscher SG, Heneghan M, et al. Grand round: autoimmune hepatitis. J Hepatol. 2019;70:773–84.

    Article  PubMed  Google Scholar 

  53. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–38.

    Article  CAS  PubMed  Google Scholar 

  54. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–76.

    Article  PubMed  Google Scholar 

  55. Czaja AJ. Diagnosis and management of autoimmune hepatitis: current status and future directions. Gut Liver. 2016;10:177–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3:1683–91.

    Article  PubMed  PubMed Central  Google Scholar 

  57. White DL, Thrift AP, Kanwal F, et al. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology. 2017;152(812–820):e815.

    Google Scholar 

  58. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.

    Article  CAS  PubMed  Google Scholar 

  59. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–74.

    Article  CAS  PubMed  Google Scholar 

  60. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97:265–72.

    Article  CAS  PubMed  Google Scholar 

  61. Ioannou GN, Bryson CL, Weiss NS, et al. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology. 2013;57:249–57.

    Article  PubMed  Google Scholar 

  62. Yu MW, Lin CL, Liu CJ, et al. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study. Gastroenterology. 2017;153(1006–1017):e1005.

    Google Scholar 

  63. Andant C, Puy H, Bogard C, et al. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol. 2000;32:933–9.

    Article  CAS  PubMed  Google Scholar 

  64. Fracanzani AL, Taioli E, Sampietro M, et al. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol. 2001;35:498–503.

    Article  CAS  PubMed  Google Scholar 

  65. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.

    Article  PubMed  Google Scholar 

  66. Schlesinger S, Aleksandrova K, Pischon T, et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol. 2013;24:2449–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.

    Article  PubMed  Google Scholar 

  68. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.

    Article  Google Scholar 

  69. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol. 2003;39:1076–84.

    Article  PubMed  Google Scholar 

  70. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89–97.

    Article  CAS  PubMed  Google Scholar 

  72. Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493–502.

    Article  CAS  PubMed  Google Scholar 

  73. Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137:110–8.

    Article  CAS  PubMed  Google Scholar 

  74. Mullhaupt B, Durand F, Roskams T, et al. Is tumor biopsy necessary? Liver Transpl. 2011;17(Suppl 2):S14–25.

    Article  PubMed  Google Scholar 

  75. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis. 2010;30:17–25.

    Article  PubMed  Google Scholar 

  76. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47:97–104.

    Article  PubMed  Google Scholar 

  77. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006;49:138–51.

    Article  CAS  PubMed  Google Scholar 

  78. Matsui O, Kobayashi S, Sanada J, et al. Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging. 2011;36:264–72.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Chou R, Cuevas C, Fu R, et al. Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Ann Intern Med. 2015;162:697–711.

    Article  PubMed  Google Scholar 

  80. Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology. 2015;275:97–109.

    Article  PubMed  Google Scholar 

  81. Mizejewski GJ. Alpha-fetoprotein as a biologic response modifier: relevance to domain and subdomain structure. Proc Soc Exp Biol Med. 1997;215:333–62.

    Article  CAS  PubMed  Google Scholar 

  82. Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005;43:434–41.

    Article  PubMed  CAS  Google Scholar 

  83. Villanueva A, Minguez B, Forner A, et al. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 2010;61:317–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570–5.

    Article  CAS  PubMed  Google Scholar 

  85. Singhal A, Jayaraman M, Dhanasekaran DN, et al. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Crit Rev Oncol Hematol. 2012;82:116–40.

    Article  PubMed  Google Scholar 

  86. Leerapun A, Suravarapu SV, Bida JP, et al. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol. 2007;5:394–402. quiz 267

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003;306:16–25.

    Article  CAS  PubMed  Google Scholar 

  88. Wang SK, Zynger DL, Hes O, et al. Discovery and diagnostic value of a novel oncofetal protein: glypican 3. Adv Anat Pathol. 2014;21:450–60.

    Article  CAS  PubMed  Google Scholar 

  89. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest. 2001;108:497–501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut. 2001;48:558–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Tangkijvanich P, Chanmee T, Komtong S, et al. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol. 2010;25:129–37.

    Article  CAS  PubMed  Google Scholar 

  92. Yasuda E, Kumada T, Toyoda H, et al. Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatol Res. 2010;40:477–85.

    Article  CAS  PubMed  Google Scholar 

  93. Jia X, Liu J, Gao Y, et al. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis. Arch Med Res. 2014;45:580–8.

    Article  CAS  PubMed  Google Scholar 

  94. Fimmel CJ, Wright L. Golgi protein 73 as a biomarker of hepatocellular cancer: development of a quantitative serum assay and expression studies in hepatic and extrahepatic malignancies. Hepatology. 2009;49:1421–3.

    Article  CAS  PubMed  Google Scholar 

  95. Kladney RD, Cui X, Bulla GA, et al. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology. 2002;35:1431–40.

    Article  CAS  PubMed  Google Scholar 

  96. Zhou Y, Yin X, Ying J, et al. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer. 2012;12:17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Xu WJ, Guo BL, Han YG, et al. Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with low AFP levels. Tumour Biol. 2014;35:12069–74.

    Article  CAS  PubMed  Google Scholar 

  98. Sulzenbacher G, Bignon C, Nishimura T, et al. Crystal structure of Thermotoga maritima alpha-L-fucosidase. Insights into the catalytic mechanism and the molecular basis for fucosidosis. J Biol Chem. 2004;279:13119–28.

    Article  CAS  PubMed  Google Scholar 

  99. El-Tayeh SF, Hussein TD, El-Houseini ME, et al. Serological biomarkers of hepatocellular carcinoma in Egyptian patients. Dis Markers. 2012;32:255–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Fawzy Montaser M, Amin Sakr M, Omar Khalifa M. Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma. Arab J Gastroenterol. 2012;13:9–13.

    Article  CAS  PubMed  Google Scholar 

  101. Naraki T, Kohno N, Saito H, et al. Gamma-Carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin. Biochim Biophys Acta. 2002;1586:287–98.

    Article  CAS  PubMed  Google Scholar 

  102. Carr BI, Kanke F, Wise M, et al. Clinical evaluation of Lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci. 2007;52:776–82.

    Article  CAS  PubMed  Google Scholar 

  103. Bertino G, Neri S, Bruno CM, et al. Diagnostic and prognostic value of alpha-fetoprotein, des-gamma-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med. 2011;102:363–71.

    CAS  PubMed  Google Scholar 

  104. Giannelli G, Antonaci S. New frontiers in biomarkers for hepatocellular carcinoma. Dig Liver Dis. 2006;38:854–9.

    Article  CAS  PubMed  Google Scholar 

  105. Giannelli G, Fransvea E, Trerotoli P, et al. Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta. 2007;383:147–52.

    Article  CAS  PubMed  Google Scholar 

  106. Pozzan C, Cardin R, Piciocchi M, et al. Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC). J Gastroenterol Hepatol. 2014;29:1637–44.

    Article  CAS  PubMed  Google Scholar 

  107. Beneduce L, Castaldi F, Marino M, et al. Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. Int J Biol Markers. 2004;19:155–9.

    Article  CAS  PubMed  Google Scholar 

  108. Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2010;10:297–308.

    Article  CAS  PubMed  Google Scholar 

  109. Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol. 2012;56:167–75.

    Article  CAS  PubMed  Google Scholar 

  110. Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open. 2012;2:e000825.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Liu J, Zhang W, Gu M, et al. Serum SP70 is a sensitive predictor of chemotherapy response in patients with advanced nonsmall cell lung cancer. Cancer Med. 2018;7:2925–33.

    Article  CAS  PubMed Central  Google Scholar 

  112. Pan S, Wang F, Huang P, et al. The study on newly developed McAb NJ001 specific to non-small cell lung cancer and its biological characteristics. PLoS One. 2012;7:e33009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Luo P, Liang C, Zhang X, et al. Identification of long non-coding RNA ZFAS1 as a novel biomarker for diagnosis of HCC. Biosci Rep. 2018;38:BSR20171359.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Qin M, Liu G, Huo X, et al. Hsa_circ_0001649: a circular RNA and potential novel biomarker for hepatocellular carcinoma. Cancer Biomark. 2016;16:161–9.

    Article  CAS  PubMed  Google Scholar 

  115. Xu H, Dong X, Chen Y, et al. Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma. Clin Chem Lab Med. 2018;56:479–84.

    Article  CAS  PubMed  Google Scholar 

  116. Nault JC, Zucman-Rossi J. TERT promoter mutations in primary liver tumors. Clin Res Hepatol Gastroenterol. 2016;40:9–14.

    Article  CAS  PubMed  Google Scholar 

  117. Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012;44:694–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    Article  CAS  PubMed  Google Scholar 

  119. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellularcarcinoma: a randomized phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.

    Article  CAS  PubMed  Google Scholar 

  120. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.

    Article  CAS  PubMed  Google Scholar 

  121. Seto WK, Mak CM, But D, et al. Mutational analysis for Wilson’s disease. Lancet. 2009;374:662.

    Article  PubMed  Google Scholar 

  122. Ala A, Walker AP, Ashkan K, et al. Wilson’s disease. Lancet. 2007;369:397–408.

    Article  CAS  PubMed  Google Scholar 

  123. Socha P, Janczyk W, Dhawan A, et al. Wilson’s disease in children: a position paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66:334–44.

    Article  PubMed  Google Scholar 

  124. Bandmann O, Weiss KH, Kaler SG. Wilson’s disease and other neurological copper disorders. Lancet Neurol. 2015;14:103–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. European Association for Study of L. EASL clinical practice guidelines: Wilson’s disease. J Hepatol. 2012;56:671–85.

    Article  Google Scholar 

  126. Das SK, Ray K. Wilson’s disease: an update. Nat Clin Pract Neurol. 2006;2:482–93.

    Article  PubMed  CAS  Google Scholar 

  127. Roberts EA, Schilsky ML, American Association for Study of Liver Diseases. Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47:2089–111.

    Article  CAS  PubMed  Google Scholar 

  128. Rodriguez-Castro KI, Hevia-Urrutia FJ, Sturniolo GC. Wilson’s disease: a review of what we have learned. World J Hepatol. 2015;7:2859–70.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Caca K, Ferenci P, Kuhn HJ, et al. High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype-genotype analysis. J Hepatol. 2001;35:575–81.

    Article  CAS  PubMed  Google Scholar 

  130. Margarit E, Bach V, Gomez D, et al. Mutation analysis of Wilson disease in the Spanish population—identification of a prevalent substitution and eight novel mutations in the ATP7B gene. Clin Genet. 2005;68:61–8.

    Article  CAS  PubMed  Google Scholar 

  131. Loudianos G, Dessi V, Lovicu M, et al. Molecular characterization of Wilson disease in the Sardinian population—evidence of a founder effect. Hum Mutat. 1999;14:294–303.

    Article  CAS  PubMed  Google Scholar 

  132. Wu Z, Wang N, Murong S, et al. Identification and analysis of mutations of the Wilson disease gene in Chinese population. Chin Med J. 2000;113:40–3.

    CAS  PubMed  Google Scholar 

  133. Hedera P. Update on the clinical management of Wilson’s disease. Appl Clin Genet. 2017;10:9–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Okada T, Shiono Y, Kaneko Y, et al. High prevalence of fulminant hepatic failure among patients with mutant alleles for truncation of ATP7B in Wilson’s disease. Scand J Gastroenterol. 2010;45:1232–7.

    Article  CAS  PubMed  Google Scholar 

  135. Nicastro E, Loudianos G, Zancan L, et al. Genotype-phenotype correlation in Italian children with Wilson’s disease. J Hepatol. 2009;50:555–61.

    Article  CAS  PubMed  Google Scholar 

  136. Houwen RH, Juyn J, Hoogenraad TU, et al. H714Q mutation in Wilson disease is associated with late, neurological presentation. J Med Genet. 1995;32:480–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Ferenci P. Phenotype-genotype correlations in patients with Wilson’s disease. Ann N Y Acad Sci. 2014;1315:1–5.

    Article  CAS  PubMed  Google Scholar 

  138. Usta J, Wehbeh A, Rida K, et al. Phenotype-genotype correlation in Wilson disease in a large Lebanese family: association of c.2299insC with hepatic and of p. Ala1003Thr with neurologic phenotype. PLoS One. 2014;9:e109727.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  139. Houwen RH, Roberts EA, Thomas GR, et al. DNA markers for the diagnosis of Wilson disease. J Hepatol. 1993;17:269–76.

    Article  CAS  PubMed  Google Scholar 

  140. Cossu P, Pirastu M, Nucaro A, et al. Prenatal diagnosis of Wilson’s disease by analysis of DNA polymorphism. N Engl J Med. 1992;327:57.

    Article  CAS  PubMed  Google Scholar 

  141. Du J, Gao B, Li L, et al. Mutation screening and prenatal diagnosis of Wilson’s disease by denature high performance liquid chromatography. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008;25:527–30.

    CAS  PubMed  Google Scholar 

  142. Lv W, Wei X, Guo R, et al. Noninvasive prenatal testing for Wilson disease by use of circulating single-molecule amplification and resequencing technology (cSMART). Clin Chem. 2015;61:172–81.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, People’s Republic of China

    Qishui Ou

  2. Tianjin First Central Hospital, Tianjin, People’s Republic of China

    Hong Mu & Chunlei Zhou

  3. Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China

    Zhaojing Zheng & Juan Geng

Authors
  1. Qishui Ou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chunlei Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhaojing Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juan Geng
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

    Shiyang Pan

  2. Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

    Jinhai Tang

Rights and permissions

Reprints and permissions

Copyright information

© 2021 People's Medical Publishing House Co. Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ou, Q., Mu, H., Zhou, C., Zheng, Z., Geng, J. (2021). Liver Diseases. In: Pan, S., Tang, J. (eds) Clinical Molecular Diagnostics. Springer, Singapore. https://doi.org/10.1007/978-981-16-1037-0_33

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-1037-0_33

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-1036-3

  • Online ISBN: 978-981-16-1037-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation